Wall Street brokerages expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to post earnings of ($0.40) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Jounce Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.02). Jounce Therapeutics reported earnings of ($0.73) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 45.2%. The firm is scheduled to report its next earnings results on Friday, November 5th.
According to Zacks, analysts expect that Jounce Therapeutics will report full year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.87) to ($0.65). For the next financial year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.64) to ($0.68). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Thursday, August 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.28. The business had revenue of $25.37 million during the quarter, compared to analysts’ expectations of $9.48 million.
NASDAQ:JNCE opened at $8.36 on Monday. Jounce Therapeutics has a 52 week low of $5.03 and a 52 week high of $14.84. The firm has a 50 day moving average of $6.75 and a 200 day moving average of $7.35. The stock has a market capitalization of $428.30 million, a price-to-earnings ratio of -15.77 and a beta of 0.97.
A number of institutional investors have recently modified their holdings of the business. Citigroup Inc. increased its stake in shares of Jounce Therapeutics by 132.5% in the second quarter. Citigroup Inc. now owns 4,673 shares of the company’s stock worth $32,000 after acquiring an additional 2,663 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Jounce Therapeutics in the first quarter worth $56,000. MML Investors Services LLC acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $68,000. Invesco Ltd. acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $76,000. Finally, Hancock Whitney Corp acquired a new stake in shares of Jounce Therapeutics in the second quarter worth $79,000. Institutional investors and hedge funds own 69.00% of the company’s stock.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.
Featured Story: Trading Ex-Dividend Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.